Back to today’s briefing

Story perspectives

FDA Begins Mifepristone Safety Study; Court Allows Mail Distribution

6/6/2026

29 3

Summary

Story summary

FDA launched a retrospective safety study of the abortion pill mifepristone.
The study will analyze hundreds of thousands of real-world cases and release interim results in July.
Final findings are scheduled for release after the November 2026 midterm elections.
The Supreme Court let mifepristone continue being mailed during the Louisiana lawsuit, despite FDA officials saying the review is science-based.

1 of 1

Story summary

FDA launched a retrospective safety study of the abortion pill mifepristone.
The study will analyze hundreds of thousands of real-world cases and release interim results in July.
Final findings are scheduled for release after the November 2026 midterm elections.
The Supreme Court let mifepristone continue being mailed during the Louisiana lawsuit, despite FDA officials saying the review is science-based.